StopDown
Launch · 29 January 2026DeepFactshealthcare AI for remote patient monitoring

DeepFacts builds AI tools to monitor patients in real time

By · Editor ·

seedFounded 2020-12
  • DeepFacts creates AI-powered devices to track patient vitals and alert doctors in real time The company raised ₹1 crore through grants and investments to…

What happened

  • DeepFacts is a healthcare startup that builds AI tools to monitor patients in real time, especially in hospital wards and rooms.
  • The company’s flagship product, proRITHM, is a wearable device that tracks key patient vitals such as heart rate, temperature, oxygen saturation, respiratory rate, and blood pressure.
  • proRITHM sends this data in real time to a cloud-based dashboard, allowing doctors and nurses to monitor patients remotely and respond quickly to changes in condition.
  • The device is designed to be worn on the chest and allows patients to move freely while still being monitored, reducing the need for frequent physical checks.
  • proRITHM includes a feature that lets doctors set personalized thresholds for each patient, triggering alerts only when readings move outside those limits.
  • The platform also calculates an early warning score to rate patient risk on a scale from one to seven, helping doctors intervene earlier if a patient’s condition worsens.
  • proRITHM is classified as a medical-grade device under Class B and is CE self-certified, with the team working toward US FDA 510(k) clearance.

Why it matters

  • The problem DeepFacts is solving is the lack of continuous monitoring for patients outside the ICU, where checks are often done only every few hours.
  • This delay in monitoring can put patients at serious risk if something goes wrong between checks.
  • proRITHM helps reduce the gap between patients and doctors by providing real-time data and early warnings.
  • The device is designed to be used in both private and public healthcare systems, addressing a global issue in quality of care and patient safety.

The business

  • DeepFacts focuses on improving patient care through real-time monitoring and early detection of health risks.
  • The company’s product, proRITHM, is a wearable device that continuously tracks patient vitals and sends data to a cloud-based dashboard.
  • The device is designed to be used in hospital wards and rooms, where monitoring is often less frequent than in ICUs.
  • proRITHM includes features like personalized thresholds, early warning scores, and mobility support to enhance patient care and reduce infection risks.
  • The company is working toward international regulatory approvals, including US FDA 510(k) clearance, to ensure its product meets global standards.

The founders

Vamsi Karatam

founder
  • Vamsi Karatam spent nearly a decade working at IBM before starting DeepFacts.
  • He founded DeepFacts in December 2020 with the goal of improving patient care through technology.
  • He has participated in startup events and accelerator programs such as IIT Bombay’s Atman 3.0 program under the THH Foundation.
  • Vamsi advises young entrepreneurs to build functional, testable products rather than waiting for a perfect one.

In numbers

₹1 crorefunds raised · 2020

Earlier rounds

  • 2020 · funding · ₹1 crore

In their words

“Instead of waiting for a perfect product, founders should focus on building something functional, testable, and adaptable as this can significantly speed up learning and growth.”Vamsi Karatam, founder

Words to know

proRITHM
DeepFacts’ flagship product, a wearable device that tracks patient vitals and sends data to a cloud-based dashboard for real-time monitoring.
Class B medical device
A classification of medical devices that requires specific regulatory compliance and testing to ensure safety and effectiveness.
early warning score
A system that rates a patient’s risk level on a scale from one to seven, helping doctors intervene earlier if a patient’s condition worsens.
FDA 510(k) clearance
A regulatory process in the United States for medical devices to demonstrate that they are substantially equivalent to a legally marketed device.

The numbers around it

Healthcare & Life Sciences in January 2026: 12 rounds with a disclosed amount, $99.0 million in all; the biggest was Sukino ($31M). Every sector this year →

Read it as a card in the app

Everything on DeepFacts → · All startup news on 29 January 2026 →

Is this DeepFacts? Get your “Featured on StopDown” badge →